doxorubicin hydrochloride / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   643 Trials   643 Trials   26774 News 


«12...4567891011121314...507508»
  • ||||||||||  cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Cold prevention of alopecia during chemotherapy: Real clinical practice. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4844;    
    The use of a cold helmet is an effective method of preventing chemotherapy-induced alopecia. Our analysis yielded a success rate of 61%, which is comparable to the worldwide data range of 50% to 80%.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Surgical decision-making after neoadjuvant chemotherapy for breast cancer. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4428;    
    Factors that are associated with choosing mastectomy include younger age at diagnosis and pre-treatment palpable axillary lymphadenopathy, which may be perceived as more advanced stage, despite no difference in stage between both groups. Regardless of surgical choice, both recurrence and mortality rates did not significantly differ between patients who chose BCS versus mastectomy, which is consistent with the literature.
  • ||||||||||  Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4185;    
    Blinded evaluation: Using data for paclitaxel, the model correctly predicted that nab-paclitaxel+gemcitabine response rates were higher than gemcitabine in metastatic pancreatic cancer (predicted LOR -0...In all 3 early breast cancer studies, predictions mirrored clinical trial results, adjuvant ECF > CMF, adjuvant TC > AC and adjuvant tamoxifen was superior to capecitabine... Our digital twin model represents transformative technology for clinical trial simulation with strong potential for accelerating and de-risking clinical drug development, and utility for synthetic control arms.
  • ||||||||||  Danyelza (naxitamab) - Y / mAbs Therap
    N9: Pilot study of novel shortened induction for high-risk neuroblastoma. (Hall A; Poster Bd #: 419) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3422;    
    P1
    N9 shows promise for reducing chemotherapy and long-term toxicity. Less chemotherapy without compromising survival is a realistic goal by virtue of the advances with anti-GD2 monoclonal antibodies which, in combination with GM-CSF+low-dose chemotherapy, are highly effective against chemo-resistant disease in bone/bone marrow.
  • ||||||||||  vincristine / Generic mfg.
    Neurofilament light chains: A biomarker for vincristine-related neuropathy. (Hall A; Poster Bd #: 243) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2862;    
    One-third of all participants were experiencing symptoms of CIPN by the third time point (cycle six of therapy), as measured by the CTCAE > 0 and the CIPN-18 > 20. Our study lays the groundwork for using Nf-L as a potential biomarker, in combination with PROs, to identify, recognize, and measure vincristine-induced neurotoxicity.
  • ||||||||||  Prevalence of cannabis related potential medication interactions (PMI) among patients with cancer during treatment. (Hall A; Poster Bd #: 202) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2823;    
    The most common cannabis-related PMIs were with acetaminophen (9.5%), dexamethasone (8%), and ondansetron (6.3%). This is one of the first studies to assess cannabis-related drug interactions in patients receiving cancer treatment, and results indicates a significant proportion of cannabis users are at risk for moderate to major PMIs including with chemotherapy.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Molecular and immunological characterization of androgen receptor expression in different breast cancer subtypes. (Hall A; Poster Bd #: 92) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2544;    
    Findings from our updated analysis based on PAM50 designation suggest a strong association between AR and PIK3CA mutations across subtypes and suggest that distinct AR-associated alterations in the immune microenvironment require further study. Exploration of specific mutations and immune-oncology markers associated with AR-H may aid in molecularly selected clinical trial design for advanced BC patients.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study. (S100bc) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2335;    
    P3
    BrECADD is significantly more effective than BEACOPP and is associated with an unprecedentedly high 4-year PFS, reducing the risk of progression, relapse or death by a third. Together with an abbreviated treatment duration of only 3 months for the majority of patients and a favorable tolerability, treatment with PET2-individualized BrECADD sets a new benchmark for the treatment of adult patients with AS-cHL.
  • ||||||||||  cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Risk of secondary leukemias in patients with germline PALB2 pathogenic variants after chemotherapy exposure. (Hall A; Poster Bd #: 125) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1648;    
    Although two subjects in the chemotherapy group developed leukemias, given the cases seen it is unlikely that these relate to the treatment exposure. Given the small sample size and retrospective nature of this study, more investigation is necessary to fully quantify the risk of therapy-related myeloid neoplasm in patients with germline PALB2 pathogenic variants.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC). (Hall A; Poster Bd #: 212a) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1357;    
    P2
    All participants initiate carboplatin (AUC 6) + docetaxel (75mg/m2) + pembrolizumab (200mg) (CbD+P) every 21 days...Regimen C (sTILs <5%) includes four cycles of CbD+P followed by four cycles of doxorubicin (60mg/m2) + cyclophosphamide (600mg/m2) + P (200mg) (AC+P)...Secondary endpoints include residual cancer burden (RCB) rates in patients with ?30% sTILs, pCR and RCB rates in patients with 5-29% and <5% sTILs, and event free and overall survival for all patients. As of January 2024, 45 of 139 participants have been enrolled.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A pilot study of early PET and biomarker dynamics in patients with stage 2 and 3 triple negative breast cancer treated with neoadjuvant response-adapted chemotherapy with pembrolizumab (NeoADAPT). (Hall A; Poster Bd #: 209b) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1352;    
    P2
    If RD is identified after surgery, adjuvant therapy will be determined by the treating oncologist, which may include pembro with AC (if not given prior), capecitabine, etc. The primary objective is to evaluate if lack of decrease in maximum FDG-PET standard uptake value of lean body mass (SULmax) by less than 40% after 1 cycle of neoadjuvant treatment correlates with RD at the time of surgery (i.e. determining the negative predictive value of FDG-PET)...Distributions of percent reduction in SULmax will be compared between pCR and no-pCR groups using the Wilcoxon rank sum test. Receiver operating characteristic (ROC) curve analysis will be performed to estimate the ability of FDG-PET SULmax reduction and cCR by MRI in predicting pCR at surgery.
  • ||||||||||  Herceptin (trastuzumab) / Roche, azeliragon (TTP488) / Cantex Pharma, Perjeta (pertuzumab) / Roche
    RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). (Hall A; Poster Bd #: 207a) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1347;    
    P1/2
    In Cohort 4, 6 patients will receive dose dense doxorubicin and cyclophosphamide (ddAC)...As of 2/1/24, 4 patients have been enrolled, with 4 undergoing screening. At the completion of this trial, we plan a randomized trial to evaluate the role of TTP488 to decrease cardiotoxicity, cancer related cognitive decline and disease recurrence.
  • ||||||||||  Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial. (Hall A; Poster Bd #: 176) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1312;    
    P2
    No correlation was observed with age; correlation of AI with response predictive subtype and other clinicopathologic features is ongoing and will be presented. Given the high incidence of AI in EBC, close monitoring in the peri/postoperative setting and education of pts and providers is critical, as risk persists even after completion of tx.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
    Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). (Hall A; Poster Bd #: 509) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_789;    
    In this study < 50% pts with advanced NF1 related MPNST made it to 2nd line CT and outcomes were inferior to the predominantly D based 1st line regimens. This highlights an area of high unmet need.
  • ||||||||||  SHR-2554 / Treeline Biosci
    Efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase 2 trial. (Hall A; Poster Bd #: 475) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_757;    
    To be eligible for inclusion, pts had to fulfill the following criteria: 8 years or older; histologically confirmed advanced or metastatic ES with loss of INI1 or upregulated mRNA level of EZH2; progressive disease after at least one line of doxorubicin-containing chemotherapy; the presence of measurable disease according to RECIST 1.1; an ECOG performance status of 0-1. SHR-2554 showed promising efficacy and an acceptable safety profile in pts with refractory ES, warranting further investigation.